Vaxcyte, Inc. — 2023 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2023. This is an annual report; standalone fourth-quarter results are not clearly provided. Vaxcyte is a clinical-stage vaccine developer with no approved products or product sales.
Business context and pipeline
The company is developing bacterial vaccines using its cell-free protein synthesis platform. Its lead programs are pneumococcal conjugate vaccine candidates VAX-24 and VAX-31. Other programs—VAX-A1 for Group A Strep, VAX-PG for periodontitis and VAX-GI for Shigella—remain preclinical.
Financial results and liquidity
| Metric | 2023 | 2022 |
|---|---|---|
| Revenue from product sales | None | None |
| Research and development expense | $332.3 million | $169.5 million |
| Acquired manufacturing rights expense | $75.0 million | $23.0 million |
| General and administrative expense | $60.7 million | $39.8 million |
| Total operating expenses | $468.0 million | $232.3 million |
| Net loss | $402.3 million | $223.5 million |
| Net loss per share, diluted | $4.14 | $3.44 |
| Net cash used in operating activities | $296.8 million | $170.6 million |
Interest income was $62.9 million, up from $8.4 million, and grant income was $4.8 million. These offset part of the operating loss; the filing reports no product revenue or gross margin. At year-end, cash and cash equivalents were $397.5 million and investments were $845.5 million, totaling $1.243 billion. Current assets were $1.096 billion and current liabilities $145.3 million. Total liabilities were $167.4 million; the filing reports no debt balance. Accumulated deficit was $924.4 million.
Operating expenses more than doubled, principally reflecting increased clinical and manufacturing activity, workforce growth, and the Sutro manufacturing-rights option exercise. The company used $773.3 million in investing activities, including investment purchases and $51.8 million of manufacturing facility and equipment construction-in-progress. Financing activities provided $639.8 million, mainly from equity offerings and ATM sales.
Material developments and outlook
- VAX-24 adult Phase 2 results showed responses meeting non-inferiority criteria for the 20 serotypes shared with PCV20 and superiority criteria for four additional serotypes; reported safety was similar to PCV20. The FDA granted Fast Track and Breakthrough Therapy designations and, following an October 2023 meeting, the company said it believed the FDA agreed with the proposed adult Phase 3 clinical design and that a field-efficacy study was not required. CMC requirements remain under discussion.
- VAX-31 entered an adult Phase 1/2 study; enrollment was completed in January 2024. The company expected topline results in Q3 2024 and planned to choose between VAX-24 and VAX-31 for an adult Phase 3 program afterward.
- If VAX-24 is selected, management expected to start its pivotal adult study in the second half of 2024, report topline results in the second half of 2025, and begin other adult Phase 3 studies in 2025–2026. If VAX-31 is selected, the company expected to begin the full potential Phase 3 program in 2025–2026. These are expectations, not guarantees.
- The VAX-24 infant Phase 2 study advanced to its final stage, with PCV20 as comparator. The company expected primary-series data by the end of Q1 2025 and booster-dose data by the end of 2025.
- In October 2023, Vaxcyte agreed to a long-term commercial manufacturing arrangement with Lonza for a dedicated Swiss facility. The company paid a CHF 27 million repurposing fee, credited over ten years after commercial production begins; specified termination circumstances could trigger a penalty of at least CHF 70 million. Year-end non-cancelable manufacturing commitments totaled $225.4 million, including $181.8 million due in 2024.
- In November 2023, Vaxcyte exercised its Sutro option for manufacturing rights, paying $50 million and accruing a further $25 million due within six months; the 2023 expense was $75 million. Up to $60 million of additional regulatory milestone payments may be due.
- After year-end, Vaxcyte completed a February 2024 follow-on offering. The filing reports approximately $816.5 million in net proceeds, excluding exercise of pre-funded warrants. Management said year-end cash and investments were expected to fund the operating plan for at least 12 months from the filing date, while also stating that substantial additional funding will be needed to complete development and commercialization.
Risks, contingencies and unusual items
- The company remains loss-making, has no commercial products, and expects substantial future spending and losses. Vaccine clinical, regulatory and commercialization success is uncertain.
- VAX-24 and VAX-31 depend on successful clinical results, FDA acceptance of surrogate immune endpoints and CMC readiness. The FDA or other regulators could require additional studies, including field-efficacy trials, or impose different requirements.
- Manufacturing is outsourced, primarily to Lonza, and the company disclosed prior process adjustments, scheduling conflicts and capacity constraints that delayed VAX-24 manufacturing. Critical raw materials and supply arrangements also present concentration risk.
- Competition is established and well-funded. Merck’s investigational V116 had positive Phase 3 results and an FDA priority-review target date of June 17, 2024, according to the filing.
- Other risks include additional financing and dilution, reimbursement and market adoption, intellectual-property challenges, foreign-exchange exposure and cybersecurity threats. Management reported no material pending legal proceeding and an unqualified audit opinion on the financial statements; the auditor also gave an unqualified opinion on internal control over financial reporting.
Important facts for investors to verify
- Subsequent VAX-31 results and the company’s choice of adult Phase 3 candidate, alongside actual FDA feedback on clinical and CMC requirements.
- Whether clinical and manufacturing timelines, costs and the stated cash runway remain achievable, including after the February 2024 offering.
- Progress, cost and operational terms of the Lonza facility buildout, manufacturing commitments and potential termination exposure.
- Enrollment and results from VAX-24 infant studies, and development progress for the preclinical pipeline.
- Competitive and regulatory developments for PCV candidates, including V116, and their implications for the standard of care and market opportunity.